Century Therapeutics, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.37
- 52-Week Range
- $0.46 – $3.04
- Market Cap
- $250.60M
- P/E (TTM)
- —
- EPS (TTM)
- -0.64
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.19
- PEG Ratio
- —
- Return on Equity
- -51.16%
- Return on Assets
- -25.52%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 8.74
- Debt/Equity
- 0.18
- Total Debt
- $37.49M
- Free Cash Flow
- $-57.54M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $170.89M
Market Snapshot
About
Century Therapeutics is a biotechnology company developing innovative cell therapies for cancer treatment. The company engineers induced pluripotent stem cells (iPSCs) to create allogeneic CAR-T and CAR-NK cell therapies that can be manufactured at scale. Century's platform aims to overcome limitations of autologous cell therapies by providing off-the-shelf treatments with improved persistence and functionality. The company is advancing multiple programs through clinical development targeting hematologic malignancies and solid tumors.